A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
NCT07543731 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5995
Last updated 2026-07-15
Summary
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Conditions
- Cardiovascular Diseases
- Atherosclerotic Cardiovascular Disease
- Hypercholesterolemia, Familial
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-02
- Primary Completion
- 2026-10-30
- Completion
- 2026-10-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
NCT04135989 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents
NCT01711931 ·Status: COMPLETED ·Phase: PHASE4
-
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
NCT07098195 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis
NCT00598533 ·Status: COMPLETED ·Phase: PHASE4
-
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
NCT05209412 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears
NCT02004730 ·Status: UNKNOWN ·Phase: PHASE4
-
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
NCT01267734 ·Status: UNKNOWN ·Phase: PHASE4
-
Drug Eluting Stent (DES) in Primary Angioplasty
NCT00759850 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
NCT01186120 ·Status: COMPLETED ·Phase: PHASE4
-
Everolimus- Versus Biolimus-Eluting Stents in All-Comers
NCT01472705 ·Status: COMPLETED
-
Single Long vs Two Short Overlapping Bioabsorbable Polymer DES
NCT01718106 ·Status: UNKNOWN ·Phase: NA
-
Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease
NCT05192616 ·Status: ACTIVE_NOT_RECRUITING
-
Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
NCT00133237 ·Status: COMPLETED ·Phase: PHASE4
-
Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent
NCT00793221 ·Status: COMPLETED ·Phase: PHASE3
-
Antiplatelet Therapy Following Stent Implantation
NCT02051361 ·Status: COMPLETED
-
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
NCT01148329 ·Status: COMPLETED
-
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
NCT01347554 ·Status: COMPLETED ·Phase: PHASE4
-
The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel
NCT00780156 ·Status: TERMINATED
-
Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease
NCT00598637 ·Status: COMPLETED ·Phase: PHASE4
-
EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
NCT03877848 ·Status: COMPLETED
-
Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)
NCT00140530 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions
NCT02796157 ·Status: UNKNOWN ·Phase: NA
-
Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent
NCT01233453 ·Status: UNKNOWN ·Phase: PHASE4
-
DESolve Post-Approval Study
NCT02013349 ·Status: COMPLETED ·Phase: NA
-
Italian Absorb Registry
NCT02298413 ·Status: UNKNOWN